Background {#Sec1}
==========

Coronavirus (COVID-19) has been termed as a global pandemic by the World Health Organization after being first diagnosed in December 2019 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>). The number of people infected with the virus is rising at an exponential rate with data from the World Health Organization (WHO) being updated regularly (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>). The mortality rate is reported to be between 1 and 5% \[[@CR1]--[@CR3]\].

There is a growing concern in physicians across specialities as the situation is evolving. A practicing neurologist is facing a difficult clinical decision in relation to disease modifying therapies in multiple sclerosis and to the risk of COVID-19.

Virology {#Sec2}
========

The coronavirus that is linked to COVID-19 is from a family of Betacoronavirus which is from the same subgenus that caused the severe acute respiratory syndrome (SARS) virus. There is a structural similarity between the receptor-binding sites. Angiotensin-converting enzyme 2 (ACE-2), for viral entry, is the proposed binding region \[[@CR4]\].

Immune response in COVID-19 {#Sec3}
===========================

The cytokine response to COVID-19 yielded a rise in inflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-2R, and IL-6) \[[@CR5]\].

Similarly, the cell response in COVID-19 patients showed a decrease in lymphocyte subsets B cells, T cells, and natural killer cells \[[@CR5]\]. There was a lower level of helper T cells and memory helper T cells while an increased percentage of naïve helper T cells in patients who had severe disease \[[@CR5]\]. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases \[[@CR5]\].

Both the rise in inflammatory cytokines and decrease in cell counts were related to the severity of the disease \[[@CR5]\].

Disease modifying therapies {#Sec4}
===========================

There are many disease modifying treatments that are available at present with difference in their mechanism of action, as shown in Table [1](#Tab1){ref-type="table"}. Table 1Disease modifying therapies and their probable risk categories (<https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf>)Disease modifying therapyMechanism of actionCOVID-19 risk category (<https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf>)*Glatiramer acetate*Shifts T cells from proinflammatory Th1 T cells to regulatory Th2 T cells reducing inflammation \[[@CR6]\]Safe to start or continueTeriflunomideInhibiting rapidly dividing activated T cells and limited action on immune system \[[@CR7]\]Safe to start or continueInterferon beta 1a, interferon beta 1bSuppresses expression of inflammatory cytokines and increases expression of anti-inflammatory cytokines \[[@CR8]\]Safe to start or continueDimethyl fumarateActivates NrF2 pathway, leading to increased humoral anti-inflammatory effects \[[@CR9]\]Safe to start or continueNatalizumabMonoclonal antibody that blocks T lymphocyte migration to CNS by interfering with α4β1-integrin receptor molecules on the surfaces of cells \[[@CR10]\]Safe to start or continue with highest efficacyFingolimodBlocks release of lymphocytes acting on S1P1-5 receptor subtype \[[@CR11]\]Moderate riskAlemtuzumabMonoclonal antibody that decreases predominantly CD-52 positive B and T cells \[[@CR12]\]Significant riskCladribineDisruption of proliferation of lymphocytes and apoptosis particularly depleting B cells (<https://www.nature.com/articles/d42859-018-00029-1>)Significant riskOcrelizumabSelectively targets the B lymphocytes that express the CD20 antigen triggers cell death (<https://www.ocrevus.com/hcp/about/moa.html>)Significant riskRituximabSelectively targets the B lymphocytes that express the CD20 antigen triggers cell death \[[@CR13]\]Significant riskSiponimodInhibits the migration of the lymphocytes to the location of the inflammation by binding to sphingosine-1-phosphate receptor \[[@CR14]\]Could pose a significant riskOfatumumabAntibody to anti-CD20 that inhibits early-stage B lymphocyte activation (<https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/3172-arzerra-ofatumumab>)\]Could pose a significant riskHematopoietic stem cell transplantation (HSCT)Should be postponed

At present, the evidence is in its preliminary phase for what is safe and what might pose an increased risk for acquiring the COVID-19 infection and may lead to severe form of the disease. The Association of British Neurologists released guidelines dividing disease modifying therapies into risk groups (<https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf>). These risk groups are shown in Table [1](#Tab1){ref-type="table"}: *Safe to start or continue*. Patients who are being started or already on interferon beta 1a, interferon beta 1b, glatiramer, teriflunomide, and dimethyl fumarate should continue it.*Safe to start or continue with highest efficacy*. Natalizumab may be considered a highly effective and safe choice in the perspective of COVID-19. It may be considered in patients with high-disease activity.*Moderate risk*. Fingolimod may increase the risk of acquiring COVID-19 or presenting with severe form of the disease; however, stopping it may get a rebound, so in these patients, benefits of continuing outweigh the risk. We do recommend these patients should be explained of these risks.*Significant risk*. Alemtuzumab, ocrelizumab, rituximab, and Cladribine may increase the risk of acquiring and severity of COVID-19. They should be carefully considered before starting in new patients and those who are scheduled for their next infusions.*Could pose a significant risk*. Ofatumumab and siponimod are not yet available in the UK or Ireland but might pose a significant risk.

Hematopoietic stem cell transplantation {#Sec5}
---------------------------------------

Undertaking HSCT may pose a significant risk to the patient and should be deferred at present considering the risk of serious COVID-19-related infection (<https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf>).

Active COVID-19 infection {#Sec6}
-------------------------

In relation to active COVID-19 infection, a discontinuation or delay of any form of disease modifying therapy should be considered (<https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf>).

Discussion {#Sec7}
==========

The current recommendation by the Association of British Neurologists (ABN) lacks class 1 evidence (<https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf>). The COVID-19 pandemic at present is expanding at an alarming rate, which may put these multiple sclerosis patients at a higher risk due to their immune status. The data from the World Health Organization (WHO) has not yet been translated in relation to this cohort of COVID-19 patients who are on disease modifying therapies. The risk estimate for the multiple sclerosis patients therefore still remains unknown.

Recommendation {#Sec8}
==============

We recommend a careful consideration of disease modifying therapies in the current health crisis which is still unfolding. In relation to multiple sclerosis, we strongly urge clinicians to educate patients on disease modifying therapies and a potential risk of COVID-19. Patients should be urged to follow strict preventative measures and if possible to postpone or defer potentially high-risk disease modifying treatments.
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